The Reply

Affiliations

¹ Cardiovascular Division, Brigham and Women's Hospital, Boston, Mass; Kidney and Hypertension Section, Joslin Diabetes Center, Boston, Mass; Departments of Medicine andSurgery,Beth Israel Deaconess Medical Center, Boston, Mass; Harvard Medical School, Boston, Mass.
² Kidney and Hypertension Section, Joslin Diabetes Center, Boston, Mass; Departments of Medicine andSurgery,Beth Israel Deaconess Medical Center, Boston, Mass; Harvard Medical School, Boston, Mass.
³ Division of Nephrology, Departmentof Medicine, University of Maryland School of Medicine, Baltimore.
⁴ Division of Nephrology, Departmentof Medicine, University of Californiaat Los Angeles, Los Angeles.
⁵ Cardiovascular Division, Brigham and Women's Hospital, Boston, Mass.
⁶ Departments of Medicine andSurgery,Beth Israel Deaconess Medical Center, Boston, Mass; Harvard Medical School, Boston, Mass; Division of Nephrology, New EnglandMedical Center, Tufts UniversitySchool of Medicine, Boston,Mass.

Comment

Larry A Weinrauch et al. Am J Med. 2018 Aug.

. 2018 Aug;131(8):e349-e351.

doi: 10.1016/j.amjmed.2018.04.003. Epub 2018 Jun 19.

¹ Cardiovascular Division, Brigham and Women's Hospital, Boston, Mass; Kidney and Hypertension Section, Joslin Diabetes Center, Boston, Mass; Departments of Medicine andSurgery,Beth Israel Deaconess Medical Center, Boston, Mass; Harvard Medical School, Boston, Mass.
² Kidney and Hypertension Section, Joslin Diabetes Center, Boston, Mass; Departments of Medicine andSurgery,Beth Israel Deaconess Medical Center, Boston, Mass; Harvard Medical School, Boston, Mass.
³ Division of Nephrology, Departmentof Medicine, University of Maryland School of Medicine, Baltimore.
⁴ Division of Nephrology, Departmentof Medicine, University of Californiaat Los Angeles, Los Angeles.
⁵ Cardiovascular Division, Brigham and Women's Hospital, Boston, Mass.
⁶ Departments of Medicine andSurgery,Beth Israel Deaconess Medical Center, Boston, Mass; Harvard Medical School, Boston, Mass; Division of Nephrology, New EnglandMedical Center, Tufts UniversitySchool of Medicine, Boston,Mass.

No abstract available

Comment on

Infection and Malignancy Outweigh Cardiovascular Mortality in Kidney Transplant Recipients: Post Hoc Analysis of the FAVORIT Trial.
Weinrauch LA, D'Elia JA, Weir MR, Bunnapradist S, Finn PV, Liu J, Claggett B, Monaco AP. Weinrauch LA, et al. Am J Med. 2018 Feb;131(2):165-172. doi: 10.1016/j.amjmed.2017.08.038. Epub 2017 Sep 21. Am J Med. 2018. PMID: 28943384 Clinical Trial.
New Onset Diabetes After Transplant: Data from the Folic Acid for Vascular Outcome Reduction in Transplantation Trial.
Wallia A, Molitch ME. Wallia A, et al. Am J Med. 2018 Aug;131(8):e347. doi: 10.1016/j.amjmed.2018.03.005. Am J Med. 2018. PMID: 30121094 No abstract available.